title: [Treatment of patients with movement and cognitive disorders in the residual period of stroke].
abstract: The efficacy and safety of axamon was studied in a trial with parallel groups in patients, aged 65-88 years, with movement and cognitive disorders in the residual period of stroke. Twenty-five patients received basic therapy and 25 patients were treated with axamon as an add-on drug in dosage of 20 mg 3 times a day during 12 weeks. Along with the neurological examination, a battery of neuropsychological scales and tests was used. The reduction of cognitive and movement deficits was observed. Axamon promotes the optimization of restoration potential of patients in the residual period of stroke.
authors.forename: B V
authors.initials: BV
authors.lastname: Agafonov
authors.forename: L A
authors.initials: LA
authors.lastname: Podrezova
authors.forename: E A
authors.initials: EA
authors.lastname: Karavashkina
authors.forename: T I
authors.initials: TI
authors.lastname: Vishniakova
authors.forename: L A
authors.initials: LA
authors.lastname: Smirnova
authors.forename: M N
authors.initials: MN
authors.lastname: Dadasheva
authors.forename: N N
authors.initials: NN
authors.lastname: Shevtsova
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010291:Paresis / Q000188:drug therapy* / Q000209:etiology; D020521:Stroke / Q000150:complications* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000634:Aminoquinolines; D002800:Cholinesterase Inhibitors; C049860:amiridine